ALONE-AF. Stopping Anticoagulation After Atrial Fibrillation Ablation

ALONE-AF: The Debate About Anticoagulation After Ablation

The atrial fibrillation is the most common sustained arrhythmia and one of the main risk factors for ischaemic stroke. Standard treatment includes oral anticoagulation, which reduces the risk of stroke but increases the likelihood of major bleeding.

International guidelines recommend continuing anticoagulation after catheter ablation according to the risk calculated with the CHA₂DS₂-VASc score, regardless of whether the procedure has been successful. In clinical practice this means at least two months of anticoagulation in all patients (after ablation) and then continuing indefinitely if thromboembolic risk is high.

The big question is whether anticoagulation can be stopped in patients with no recurrence of atrial fibrillation after an apparently successful ablation. The ALONE-AF trial, published in JAMA, provides randomised data that help answer it.


ALONE-AF: Trial Design

The ALONE-AF trial was a randomised, open-label clinical study with event follow-up through national health registries.

Main Inclusion Criteria:

  • Patients with non-valvular atrial fibrillation.
  • Having had a first catheter ablation of the pulmonary veins.
  • No recurrence of arrhythmia for at least twelve months after the procedure.
  • At least one stroke risk factor on the CHA₂DS₂-VASc score.

Intervention:
Participants were randomly assigned to two strategies:

  1. Continue oral anticoagulation using direct oral anticoagulants such as apixaban, rivaroxaban or edoxaban.
  2. Stop anticoagulation after the recurrence-free period.

Primary Endpoint:
The primary endpoint was a composite of ischaemic stroke, systemic embolism or major bleeding over 24 months of follow-up.

840 patients were included, with a mean age of 64 years and 25% women.


ALONE-AF. Main Results: Fewer Net Events When Anticoagulation Is Stopped

After 24 months of follow-up, the group that continued oral anticoagulation had more primary endpoint events than the group that stopped it.

  • Anticoagulation group: 2.2% events.
  • No-anticoagulation group: 0.3% events.

This difference was mainly due to a higher incidence of major bleeding in the group that continued anticoagulation (1.4% versus 0%). Rates of ischaemic stroke or systemic embolism were very low and similar in both groups (0.8% versus 0.3%), with no statistically significant differences.

In short, in patients with no recurrence of atrial fibrillation for at least one year after ablation, stopping anticoagulation reduced net clinical events through less bleeding, with no signs of more strokes or emboli.


ALONE-AF. Clinical Implications and Limitations

Patient Selection: The benefit was seen in carefully selected patients, with no recurrence of atrial fibrillation for at least twelve months and with controlled risk factors.

Risk-Benefit Balance: The trial shows that, in this profile, the excess of major bleeding with anticoagulation outweighs the marginal benefit in stroke prevention, at least in the short term.

Alignment With Guidelines: Current guidelines recommend continuing anticoagulation based on the CHA₂DS₂-VASc score. This trial does not contradict that recommendation, but opens the door to a de-escalation strategy in very selected subgroups.

Limitations: The trial lasted 24 months and had few ischaemic events, so it cannot rule out small differences in longer-term stroke risk. It was also carried out in centres with intensive monitoring, which may not be reproducible in all health systems.


Conclusion: Towards Personalised Anticoagulation After Ablation

The ALONE-AF trial suggests that stopping oral anticoagulation after atrial fibrillation ablation may be safe in patients with no recurrence for at least twelve months and may reduce net events by avoiding major bleeding.

These findings support moving towards truly personalised anticoagulation, based not only on the risk score but also on the absence of recurrences and the capacity for clinical monitoring.

Test yourself: atrial fibrillation quiz (2024)37 questions with explanations · free
Start the test

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *